ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.

Trial Details

NCT ID
NCT06656494
Phase
PHASE1
Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • ICP-248
  • Azacitidine
Locations (sample)
  • Orange, California, United States|33.78779,-117.85311
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Tampa, Florida, United States|27.94752,-82.45843
  • New York, New York, United States|40.71427,-74.00597
  • Chapel Hill, North Carolina, United States|35.9132,-79.05584

Key Eligibility Criteria

  • Eligible subjects must meet all of the following criteria:
  • Subject must have confirmation of diagnosis of AML (except for acute promyelocytic leukemia \[APL\]) or MDS per 2016 World Health Organization (WHO…
  • For AML (except for APL) cohort:
  • Previously treated relapsed/refractory AML subjects

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →